Literature DB >> 18556464

Chaperone displacement from mutant cystic fibrosis transmembrane conductance regulator restores its function in human airway epithelia.

Fei Sun1, Zhibao Mi, Steven B Condliffe, Carol A Bertrand, Xiaoyan Gong, Xiaoli Lu, Ruilin Zhang, Joseph D Latoche, Joseph M Pilewski, Paul D Robbins, Raymond A Frizzell.   

Abstract

Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause cystic fibrosis (CF). The most common mutation, DeltaF508, omits the phenylalanine residue at position 508 in the first nucleotide binding domain (NBD1) of CFTR. The mutant protein is retained in the endoplasmic reticulum and degraded by the ubiquitin-proteasome system. We demonstrate that expression of NBD1 plus the regulatory domain (RD) of DeltaF508 CFTR (DeltaFRD) restores the biogenesis of mature DeltaF508 CFTR protein. In addition, DeltaFRD elicited a cAMP-stimulated anion conductance response in primary human bronchial epithelial (HBE) cells isolated from homozygous DeltaF508 CF patients. A protein transduction domain (PTD) could efficiently transduce (approximately 90%) airway epithelial cells. When fused to a PTD, direct addition of the DeltaFRD peptide conferred a dose-dependent, cAMP-stimulated anion efflux to DeltaF508 HBE cells. Hsp70 and Hsp90 associated equally with WT and DeltaF508 CFTR, whereas nearly twice as much of the Hsp90 cochaperone, Aha1, associated with DeltaF508 CFTR. Expression of DeltaFRD produced a dose-dependent removal of Aha1 from DeltaF508 CFTR that correlated with its functional rescue. These findings indicate that disruption of the excessive association of the cochaperone, Aha1, with DeltaF508 CFTR is associated with the correction of its maturation, trafficking and regulated anion channel activity in human airway epithelial cells. Thus, PTD-mediated DeltaFRD fragment delivery may provide a therapy for CF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18556464      PMCID: PMC2518260          DOI: 10.1096/fj.07-105338

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  48 in total

Review 1.  Chaperoning the maturation of the cystic fibrosis transmembrane conductance regulator.

Authors:  J L Brodsky
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-07       Impact factor: 5.464

2.  Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo.

Authors:  Z Mi; J Mai; X Lu; P D Robbins
Journal:  Mol Ther       Date:  2000-10       Impact factor: 11.454

3.  Protein kinase A associates with cystic fibrosis transmembrane conductance regulator via an interaction with ezrin.

Authors:  F Sun; M J Hug; N A Bradbury; R A Frizzell
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

4.  E3KARP mediates the association of ezrin and protein kinase A with the cystic fibrosis transmembrane conductance regulator in airway cells.

Authors:  F Sun; M J Hug; C M Lewarchik; C H Yun; N A Bradbury; R A Frizzell
Journal:  J Biol Chem       Date:  2000-09-22       Impact factor: 5.157

5.  Pharmacological modulation of ion transport across wild-type and DeltaF508 CFTR-expressing human bronchial epithelia.

Authors:  D C Devor; R J Bridges; J M Pilewski
Journal:  Am J Physiol Cell Physiol       Date:  2000-08       Impact factor: 4.249

6.  Rescue of functional DeltaF508-CFTR channels by co-expression with truncated CFTR constructs in COS-1 cells.

Authors:  Grzegorz Owsianik; Lishuang Cao; Bernd Nilius
Journal:  FEBS Lett       Date:  2003-11-06       Impact factor: 4.124

7.  In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis.

Authors:  Guodong Cao; Wei Pei; Hailiang Ge; Qinhua Liang; Yumin Luo; Frank R Sharp; Aigang Lu; Ruiqiong Ran; Steven H Graham; Jun Chen
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

8.  Coordinated nonvectorial folding in a newly synthesized multidomain protein.

Authors:  Annemieke Jansens; Esther van Duijn; Ineke Braakman
Journal:  Science       Date:  2002-12-20       Impact factor: 47.728

9.  Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein.

Authors:  Ying Wang; Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  J Biol Chem       Date:  2007-10-02       Impact factor: 5.157

10.  Building an understanding of cystic fibrosis on the foundation of ABC transporter structures.

Authors:  Juan L Mendoza; Philip J Thomas
Journal:  J Bioenerg Biomembr       Date:  2007-12       Impact factor: 2.945

View more
  31 in total

1.  Functional rescue of a misfolded eukaryotic ATP-binding cassette transporter by domain replacement.

Authors:  Raymond J Louie; Silvere Pagant; Ji-Young Youn; John J Halliday; Gregory Huyer; Susan Michaelis; Elizabeth A Miller
Journal:  J Biol Chem       Date:  2010-09-14       Impact factor: 5.157

2.  Hsp90 cochaperone Aha1 is a negative regulator of the Saccharomyces MAL activator and acts early in the chaperone activation pathway.

Authors:  Fulai Ran; Nidhi Gadura; Corinne A Michels
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

Review 3.  Intracellular α(2C)-adrenoceptors: storage depot, stunted development or signaling domain?

Authors:  Maqsood A Chotani; Nicholas A Flavahan
Journal:  Biochim Biophys Acta       Date:  2011-05-14

4.  The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9.

Authors:  Carol A Bertrand; Shalini Mitra; Sanjay K Mishra; Xiaohui Wang; Yu Zhao; Joseph M Pilewski; Dean R Madden; Raymond A Frizzell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-03-30       Impact factor: 5.464

5.  FK506 binding protein 8 peptidylprolyl isomerase activity manages a late stage of cystic fibrosis transmembrane conductance regulator (CFTR) folding and stability.

Authors:  Darren M Hutt; Daniela Martino Roth; Monica A Chalfant; Robert T Youker; Jeanne Matteson; Jeffrey L Brodsky; William E Balch
Journal:  J Biol Chem       Date:  2012-04-02       Impact factor: 5.157

6.  S-Nitrosothiols increases cystic fibrosis transmembrane regulator expression and maturation in the cell surface.

Authors:  Khalequz Zaman; Deric Bennett; Maya Fraser-Butler; Zivi Greenberg; Paulina Getsy; Abdus Sattar; Laura Smith; Deborah Corey; Fei Sun; John Hunt; Stephen J Lewis; Benjamin Gaston
Journal:  Biochem Biophys Res Commun       Date:  2014-01-03       Impact factor: 3.575

7.  Biological and structural basis for Aha1 regulation of Hsp90 ATPase activity in maintaining proteostasis in the human disease cystic fibrosis.

Authors:  Atanas V Koulov; Paul LaPointe; Bingwen Lu; Abbas Razvi; Judith Coppinger; Meng-Qiu Dong; Jeanne Matteson; Rob Laister; Cheryl Arrowsmith; John R Yates; William E Balch
Journal:  Mol Biol Cell       Date:  2010-01-20       Impact factor: 4.138

8.  The primary folding defect and rescue of ΔF508 CFTR emerge during translation of the mutant domain.

Authors:  Hanneke Hoelen; Bertrand Kleizen; Andre Schmidt; John Richardson; Paraskevi Charitou; Philip J Thomas; Ineke Braakman
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

Review 9.  Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.

Authors:  Gary E L Brandt; Brian S J Blagg
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

10.  SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia.

Authors:  Carol A Bertrand; Ruilin Zhang; Joseph M Pilewski; Raymond A Frizzell
Journal:  J Gen Physiol       Date:  2009-03-16       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.